Company News

John B. Landis, Ph.D. Joins SAB

Kalamazoo, MI (November 13, 2008) – NanoMed Pharmaceuticals, Inc. announced today that John B. Landis, Ph.D. has joined its Scientific Advisory Board.  Dr. Landis has 30 years of leadership experience in pharmaceutical research and development and has helped develop over 40 new medications, including Camptosar for colorectal cancer.

NanoMed Pharmaceuticals Founder Joins Faculty at UNC School of Pharmacy

Russell Mumper, PhD, (July 12, 2007) an internationally recognized leader in the pharmaceutical applications of nanotechnology, has joined the UNC School of Pharmacy as the John A. McNeill Distinguished Professor.

NanoMed Pharmaceuticals Hires Chief Scientific Officer

KALAMAZOO, MI, (June 21, 2007)– NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that it has hired Harry C. Ledebur, Jr., PhD. to serve as the company’s Vice President Research & Development, Chief Scientific Officer. Prior to joining NanoMed, Dr. Ledebur was Vice President, Operations & Scientific Affairs for Chromos Molecular Systems, Inc. where he was a member of Chromos’ Executive Committee and was responsible for all discovery and product development programs along with quality systems, regulatory affairs and site operations.

NanoMed Pharmaceuticals Elects Gabriel Leung to Board

Current President of OSI Oncology Has Significant R&D and Commercial Expertise

KALAMAZOO, MI, (May 22, 2007) – NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that it has elected to its Board of Directors, Gabriel Leung, President, Oncology, at OSI Pharmaceuticals, a leading biotechnology company and maker of Tarceva®.

NanoMed Pharmaceuticals Achieves Preclinical Development Milestone; Completes Second Closing of Series A Financing

KALAMAZOO, MI., (January 31, 2007) – NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced that it has achieved its preclinical development milestone for the company’s lead oncology product which is intended to overcome multidrug resistance in remission induction therapy in elderly acute myeloid leukemia (AML) patients. As a result, the company has completed the second closing of its Series A Convertible Preferred Stock investment by the SWMF Life Science Venture Fund.

NanoMed Pharmaceuticals Founders Issued Broad Patent for Novel Method to Make Nanoparticles

Nanotemplate Engineering Being Used to Develop New AML Drug

KALAMAZOO, MI., (January 3, 2007) – NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced today that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled “Microemulsions As Precursors To Solid Nanoparticles.” Their invention, assigned to the University of Kentucky Research Foundation and licensed exclusively to NanoMed Pharmaceuticals, covers processes and applications of Nanotemplate Engineering, a nanoparticle manufacturing technology used to formulate small molecules, peptides, proteins, plasmid DNA, and diagnostic agents.

NanoMed Pharmaceuticals Awarded STTR to Further Develop Botanical Drug for Oral Cancer Chemoprevention

Potential New Treatment Option For Precancerous Lesions May Delay Or Prevent Progression To Oral Squamous Cell Carcinoma

KALAMAZOO, MI., (September 13, 2006) – NanoMed Pharmaceuticals, Inc., an advanced drug delivery company developing therapeutic and diagnostic products to treat or detect disease, announced today that it has been awarded a Small Business Technology Transfer (STTR) grant by the National Institutes of Health, National Center for Complimentary and Alternative Medicine, for “Bioadhesive Gels for Oral Cancer Chemoprevention.” The work funded by this Phase I grant will be completed at the company’s laboratory located in the University of Kentucky’s Advanced Science & Technology Commercialization Center, and in collaboration with researchers at the University of Kentucky and The Ohio State University.

NanoMed Pharmaceuticals Awarded STTR for Nanotemplate Engineering of a Novel Molecular Imaging Agent

Goal Is Superior Magnetic Resonance Images For The Early Diagnosis Of Tumors And Rapid Intervention In The Treatment Of Cancer

KALAMAZOO, MI., (September 7, 2006) – NanoMed Pharmaceuticals, Inc., an advanced drug delivery company developing nanoparticle-based therapeutic and diagnostic products to treat or detect disease, announced today that it has been awarded a Small Business Technology Transfer (STTR) grant by the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering for “Nanotemplate Engineering of a Stealth MRI Contrast Agent.” The work funded by this Phase I grant will be completed at the company’s laboratory located in the University of Kentucky’s Advanced Science & Technology Commercialization Center.

NanoMed Pharmaceuticals Closes Initial Financing

Investment Led By SWMF Life Science Venture Fund

KALAMAZOO, MI., (July 5, 2006) – NanoMed Pharmaceuticals, Inc., an advanced drug delivery company developing nanoparticle-based therapeutic and diagnostic products to treat or detect disease, announced today that it has closed on its first round of venture financing. The investment was led by the SWMF Life Science Venture Fund, a $50 million private equity fund investing exclusively in promising life science companies having a presence in the Kalamazoo Region.

NanoMed Pharmaceuticals Founders Issued Patent for Use of Nanoparticles to Detect Radioisotopes

“NanoScintillation Systems” Detect Carbon-14 Without the Use of Organic Solvents; Nanoparticle-Based System Would Reduce Hazardous Environmental Waste

LEXINGTON, KY and KALAMAZOO, MI., (November 29, 2005) – NanoMed Pharmaceuticals, Inc. founders Michael Jay, Ph.D. and Russell J. Mumper, Ph.D. have been issued U.S. Patent 6,855,270 entitled “NanoScintillation Systems For Aqueous-Based Liquid Scintillation Counting.” Their invention, assigned to the University of Kentucky Research Foundation and licensed exclusively to NanoMed Pharmaceuticals, covers processes to make nanoparticle-based NanoScintillation Systems which are used to detect beta-particle- or alpha-particle-emitting radioisotopes without the use of the organic solvents commonly used in conventional liquid scintillation (LS) “cocktails”.